吉西他滨联合紫杉醇对比吉西他滨单药用于既往接受5-氟尿嘧啶、奥沙利铂和伊立替康治疗的转移性胰腺癌:随机III期PRODIGE 65-UCGI 36-GEMPAX UNICANCER研究
GEMPAX为开放标签随机III期试验,在既往接受5-氟尿嘧啶、奥沙利铂和伊立替康的转移性胰腺导管腺癌患者中比较吉西他滨联合紫杉醇与吉西他滨单药的二线疗效。联合组未达到OS主要终点,但PFS和ORR显著改善,≥3级治疗相关不良事件发生率更高。
要点
- 联合组中位OS 6.4个月 vs 单药组5.9个月,HR 0.87,P=0.4095,未达主要终点。
- 联合组中位PFS 3.1个月 vs 单药组2.0个月,HR 0.64,P=0.0067。
- 联合组ORR 17.1% vs 单药组4.2%,P=0.008。
核心结论
- GEMPAX方案在转移性胰腺导管腺癌二线治疗中未达到OS主要终点,但PFS和ORR显著改善。
研究设计与样本
- 开放标签、随机III期临床试验,纳入211例组织学或细胞学确诊的转移性胰腺导管腺癌患者,按2:1随机分配至GEMPAX组(A组)或吉西他滨单药组(B组)。
- A组:紫杉醇80 mg/m²+吉西他滨1,000 mg/m²,静脉给药,第1、8、15天,每28天重复;B组:吉西他滨单药,第1、8、15天,每28天重复,直至进展、毒性或患者决定。
- 主要终点为总生存期,次要终点包括无进展生存期、客观缓解率、生活质量和安全性。
主要发现
- 中位年龄64岁(范围30-86岁),男性占62%。
- 存活患者中位随访时间A组13.4个月 vs B组13.8个月。
- 中位OS:A组6.4个月(95%CI 5.2-7.4) vs B组5.9个月(95%CI 4.6-6.9),HR 0.87(95%CI 0.63-1.20),P=0.4095。
- 中位PFS:A组3.1个月(95%CI 2.2-4.3) vs B组2.0个月(95%CI 1.9-2.3),HR 0.64(95%CI 0.47-0.89),P=0.0067。
- ORR:A组17.1%(95%CI 11.3-24.4) vs B组4.2%(95%CI 0.9-11.9),P=0.008。
关键数值与推荐
- 因不良事件终止治疗:A组16.7% vs B组2.9%。
- A组报告1例与吉西他滨和紫杉醇均相关的5级不良事件(急性呼吸窘迫)。
- ≥3级治疗相关不良事件:A组58.0% vs B组27.1%;贫血15.2% vs 4.3%,中性粒细胞减少15.9% vs 15.7%,血小板减少19.6% vs 4.3%,乏力10.1% vs 2.9%,神经病变12.3% vs 0.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: GEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received 5-fluorouracil, oxaliplatin, and irinotecan. METHODS: Patients with histologically or cytologically confirmed mPDAC were randomly assigned (2:1) to receive GEMPAX (paclitaxel 80 mg/m2 + gemcitabine 1,000 mg/m2; IV; once at day (D) 1, D8, and D15/arm A) or gemcitabine (arm B) alone once at D1, D8, and D15 every 28 days until progression, toxicity, or patient's decision. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), objective response rate (ORR), quality of life, and safety. RESULTS: Overall, 211 patients (median age, 64 [30-86] years; 62% male) were included. After a median study follow-up for alive patients of 13.4 versus 13.8 months in arm A versus arm B, the median OS (95% CI) was 6.4 (5.2 to 7.4) versus 5.9 months (4.6 to 6.9; hazard ratio [HR], 0.87 [0.63 to 1.20]; P = 0.4095), the median PFS was 3.1 (2.2 to 4.3) versus 2.0 months (1.9 to 2.3; HR, 0.64 [0.47 to 0.89]; P = 0.0067), and the ORR was 17.1% (11.3 to 24.4) versus 4.2% (0.9 to 11.9; P = 0.008) in arm A versus arm B, respectively. Overall, 16.7% of patients in arm A and 2.9% in arm B discontinued their treatment because of adverse events (AEs). One grade 5 AE associated with both gemcitabine and paclitaxel was reported in arm A (acute respiratory distress), and 58.0% versus 27.1% of patients experienced grade ≥3 treatment-related AEs in arm A versus arm B, among which 15.2% versus 4.3% had anemia, 15.9% versus 15.7% had neutropenia, 19.6% versus 4.3% had thrombocytopenia, 10.1% versus 2.9% had asthenia and 12.3% versus 0.0% had neuropathy. CONCLUSION: While GEMPAX did not meet the primary end point of OS versus gemcitabine alone in patients with mPDAC in the second-line setting, both PFS and ORR were significantly improved.
引用
- De La Fouchardière C, Malka D, Cropet C, et al. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study. J Clin Oncol. 2024. PMID: 38232341. doi:10.1200/JCO.23.00795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。